Merrimack Pharmaceuticals Weighs Dissolution Post FDA Approval
Company Announcements

Merrimack Pharmaceuticals Weighs Dissolution Post FDA Approval

Merrimack Pharmaceuticals Inc. (MACK) has released an update.

Merrimack Pharmaceuticals, Inc. has announced FDA approval of Onivyde as a first-line treatment for metastatic pancreatic cancer, leading to a $225 million milestone payment from Ipsen. Merrimack’s Board is considering a corporate dissolution and plans to distribute this payment and other assets to shareholders after expenses. They will seek shareholder approval at a special meeting in May 2024 and have noted that plans for dissolution could change if no longer deemed beneficial for shareholders.

For further insights into MACK stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TipRanks Auto-Generated NewsdeskMerrimack Pharmaceuticals Approves Liquidation and Dividend
TipRanks Auto-Generated NewsdeskMerrimack Pharmaceuticals Plans Liquidating Dividend
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App